Cara Therapeutics Valuation
| 69C Stock | EUR 4.84 0.00 0.00% |
At this time, the firm appears to be overvalued. Cara Therapeutics shows a prevailing Real Value of €3.53 per share. The current price of the firm is €4.84. Our model approximates the value of Cara Therapeutics from analyzing the firm fundamentals such as Profit Margin of (2.25) %, current valuation of 450.58 M, and Return On Equity of -0.45 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Cara Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Cara Therapeutics is based on 3 months time horizon. Increasing Cara Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Cara stock is determined by what a typical buyer is willing to pay for full or partial control of Cara Therapeutics. Since Cara Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cara Stock. However, Cara Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.84 | Real 3.53 | Hype 4.84 |
The real value of Cara Stock, also known as its intrinsic value, is the underlying worth of Cara Therapeutics Company, which is reflected in its stock price. It is based on Cara Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cara Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Cara Therapeutics helps investors to forecast how Cara stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cara Therapeutics more accurately as focusing exclusively on Cara Therapeutics' fundamentals will not take into account other important factors: Cara Therapeutics Total Value Analysis
Cara Therapeutics is presently estimated to have takeover price of 450.58 M with market capitalization of 508.24 M, debt of 4.99 M, and cash on hands of 134.45 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Cara Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
450.58 M | 508.24 M | 4.99 M | 134.45 M |
Cara Therapeutics Investor Information
About 16.0% of the company shares are owned by insiders or employees . The book value of Cara Therapeutics was presently reported as 3.44. The company recorded a loss per share of 1.5. Cara Therapeutics had not issued any dividends in recent years. Based on the key indicators related to Cara Therapeutics' liquidity, profitability, solvency, and operating efficiency, Cara Therapeutics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in February.Cara Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cara Therapeutics has an asset utilization ratio of 9.32 percent. This implies that the Company is making €0.0932 for each dollar of assets. An increasing asset utilization means that Cara Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Cara Therapeutics Ownership Allocation
Cara Therapeutics holds a total of 53.73 Million outstanding shares. Over half of Cara Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Cara Therapeutics. Please watch out for any change in the institutional holdings of Cara Therapeutics as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cara Therapeutics Profitability Analysis
The company reported the revenue of 23.03 M. Net Loss for the year was (88.44 M) with loss before overhead, payroll, taxes, and interest of (59.67 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Cara Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Cara Therapeutics and how it compares across the competition.
About Cara Therapeutics Valuation
The stock valuation mechanism determines Cara Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Cara Therapeutics. We calculate exposure to Cara Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cara Therapeutics's related companies.Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut. Cara Therapeutics operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 55 people.
8 Steps to conduct Cara Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Cara Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Cara Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Cara Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Cara Therapeutics' revenue streams: Identify Cara Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Cara Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Cara Therapeutics' growth potential: Evaluate Cara Therapeutics' management, business model, and growth potential.
- Determine Cara Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Cara Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Cara Stock analysis
When running Cara Therapeutics' price analysis, check to measure Cara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cara Therapeutics is operating at the current time. Most of Cara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cara Therapeutics' price. Additionally, you may evaluate how the addition of Cara Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Stocks Directory Find actively traded stocks across global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |